Quarterly report pursuant to Section 13 or 15(d)

Schedule of Accrued Expenses (Details)

v3.22.2.2
Schedule of Accrued Expenses (Details) - USD ($)
Sep. 30, 2022
Dec. 31, 2021
Payables and Accruals [Abstract]    
Payroll and incentives $ 1,462,000 $ 1,343,000
Deferred revenue * [1] 1,408,000 33,000
Research and development expenses 334,000 381,000
General and administrative expenses 299,000 195,000
Other deferred liabilities ** [2] 194,000 899,000
Total $ 3,696,932 $ 2,850,888
[1] At September 30, 2022, the balance included $1,375 thousand related to an exclusive research collaboration with BioNTech SE (the “BioNTech Agreement”) and $33 thousand is related to a feasibility study agreement with Genentech, Inc. (the “Genentech Agreement”), which is expected to be recognized by December 31, 2022. At December 31, 2021, the balance of $33 thousand was related to the Genentech Agreement. The balance of the BioNTech Agreement will be recognized evenly over the next six months. (See Note 9 – Revenue Recognition, Collaboration Agreements and Other).
[2] At September 30, 2022 and December 31, 2021, the balances of $194 thousand and $899 thousand, respectively, related to an award agreement with the Cystic Fibrosis Foundation (the “CFF Agreement). (See Note 9 – Revenue Recognition, Collaboration Agreements and Other).